国发股份(600538) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥87,573,304.73, representing a decrease of 13.79% compared to the same period last year[5] - The net profit attributable to shareholders of the listed company was a loss of ¥12,357,990.80, with basic and diluted earnings per share both at -¥0.02[5] - The net cash flow from operating activities was -¥22,788,943.33, indicating a negative cash flow situation[5] - Total operating revenue for Q1 2024 was ¥87,573,304.73, a decrease of 13.8% compared to ¥101,579,609.22 in Q1 2023[20] - The net loss for Q1 2024 was ¥11,674,707.20, compared to a net loss of ¥2,122,373.30 in Q1 2023, indicating a significant increase in losses[21] - The gross profit margin for Q1 2024 was approximately -4.2%, compared to a positive margin in the previous year, highlighting a challenging operational environment[20] - Basic and diluted earnings per share for Q1 2024 were both -¥0.02, compared to -¥0.01 in Q1 2023, indicating worsening profitability on a per-share basis[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,042,011,145.71, down 1.28% from the end of the previous year[6] - The equity attributable to shareholders of the listed company decreased by 1.42% to ¥856,879,175.03 compared to the end of the previous year[6] - As of March 31, 2024, the total current assets amounted to RMB 515,217,121.82, a slight decrease from RMB 519,119,996.42 on December 31, 2023, representing a decline of approximately 0.35%[16] - The total liabilities as of March 31, 2024, were not explicitly stated but are critical for assessing the company's financial health[16] - Total liabilities decreased to ¥174,381,338.18 in Q1 2024 from ¥176,216,189.27 in Q1 2023, showing a slight improvement in the company's leverage[18] - The equity attributable to shareholders decreased to ¥856,879,175.03 in Q1 2024 from ¥869,237,165.83 in Q1 2023, reflecting the impact of net losses on shareholder value[18] Cash Flow - The cash and cash equivalents decreased from RMB 155,261,413.75 to RMB 133,760,753.06, reflecting a reduction of about 14.00%[16] - In Q1 2024, the cash inflow from operating activities was $83,795,116.71, a decrease of 1.54% compared to $85,107,320.59 in Q1 2023[25] - The cash outflow from operating activities totaled $106,584,060.04, down 6.9% from $114,513,249.27 in the same period last year[25] - The net cash flow from operating activities was -$22,788,943.33, an improvement from -$29,405,928.68 in Q1 2023[25] - Cash inflow from investment activities was $10,000.00, significantly lower than $10,000,000.00 in Q1 2023[26] - The net cash flow from investment activities was -$1,048,505.35, compared to a positive $6,314,909.04 in the previous year[26] - Cash inflow from financing activities was $1,800,000.00, while cash outflow was $294,114.20, resulting in a net cash flow of -$294,114.20, down from $1,433,872.36 in Q1 2023[26] - The ending cash and cash equivalents balance was $118,815,433.10, a decrease from $126,184,836.92 at the end of Q1 2023[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,303[11] - The controlling shareholder, Zhu Rongjuan, has 75,400,542 shares, which is 14.38% of the total shares, with 100% of her shares being judicially frozen[14] - The total number of shares pledged by Zhu Rongjuan is 52,440,000, which is 69.55% of her holdings[14] - The company reported that 80,713,000 shares, or 75.20% of the total pledged shares, are under judicial freeze[14] - The company is actively monitoring the impact of judicial auctions on shareholder equity, with 15 million shares auctioned in January and April 2024[13] - There are no significant changes in the top 10 shareholders or their shareholding status due to the absence of transfer or lending activities[13] Operational Challenges - The decline in revenue was attributed to decreased customer demand and budget cuts affecting the subsidiary Guangzhou Gaosheng Biotechnology Co., Ltd.[8] - Increased advertising expenses for promoting the "Pearl Eye Drops" product contributed to the overall loss in the quarter[9] - The company reported a loss of ¥7,990,000 from its investment in the "Co-Winning No. 1 Fund" due to declines in stock prices of invested projects[9] - The company has not disclosed any new product developments or market expansion strategies in this quarter[16] - Research and development expenses for Q1 2024 were ¥1,684,223.54, slightly up from ¥1,664,937.32 in Q1 2023, indicating continued investment in innovation[20] - The company reported an investment loss of ¥7,768,571.71 in Q1 2024, compared to a loss of ¥6,297,784.29 in Q1 2023, suggesting challenges in its investment portfolio[20]